Adnexus is a Texas-based biotech company committed to the development and commercialization of its proprietary proteins and monoclonal antibodies for the treatment of infectious diseases.
Our company, Adnexus, has developed a unique and innovative approach to producing antibodies that target specific sites on viruses. This process involves using Artificial Intelligence to identify conserved and immutable targets, which we can then analyze for linearity, accessibility by antibodies, neutralizability, and the effect of mutations.
Our proprietary methodology starts with human “immune-B cells” from individuals who have recovered from the target virus. This process is unique because it uses human cells obtained from natural infections, which allows us to create fully human monoclonal antibodies with natural affinity and specificity. These antibodies target the conserved and immutable sites on the surface envelope proteins of the virus, which prevents the virus from escaping the antibodies. When used as a therapeutic, our antibodies have a lower risk of immunogenicity.
Our monoclonal antibodies are universal, durable, broadly neutralizing, and unaffected by mutations or “virus escape.”
For more information on our services and research projects, please click here to submit an enquiry.
